Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 252-260

  MacVicar, Gary R ^a   Hussain, Maha H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

androgen receptor; castration resistance; metastatic prostate cancer; targeted therapy

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CABOZANTINIB; CALCITRIOL; CIXUTUMUMAB; CUSTIRSEN; DASATINIB; DOCETAXEL; ENZALUTAMIDE; EVEROLIMUS; GALETERONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; LENALIDOMIDE; MITOXANTRONE; ORTERONEL; PREDNISOLONE; RAMUCIRUMAB; SATRAPLATIN; SIPULEUCEL T; SUNITINIB; TASQUINIMOD; TEMSIROLIMUS; UNINDEXED DRUG; VORINOSTAT; ZIBOTENTAN;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84876287522     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835ff161     Document Type: Review

References (51)

1. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). In: 2009 Genitourinary Cancers Symposium; 2009. p. LBA150.
2. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-148.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
5. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immu-notherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castrationresistant prostate cancer (CRPC). In: 2009 Genitourinary Cancers Symposium; 2009. p. 7.
6. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29:2191-2198.
7. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30:1534-1540.
8. Quinn DI, Tangen CM, Hussain M, et al. SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol 2012; 30:(Suppl; abstr 4511).
9. Petrylak DP, Fizazi K, Sternberg CN, et al. A phase 3 study of evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lana-lidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL Trial. Ann Oncol 2012; 23:abstr LBA24.
10. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27:5431-5438.
11. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
12. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
13. Michaelson MD, Oudard S, Ou Y, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011; 29(Suppl):abstr 4515.
14. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197.
15. Parker C, Coleman RE, Nilsson S, et al. Updated survival, quality of life (QOL), and safety data of radium-223 chloride (RA-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). Ann Oncol 2012; 23:abstr 898PD.
16. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55:1269-1277.
17. Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007; 25:(Suppl, abstr 5015).
18. Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. In: 2012 ASCO Annual Meeting 2012; Chicago, IL; 2012. p. Suppl; abstr 4.
19. Moinpour C, Berry DL, Ely B, et al. Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)-Phase III. J Clin Oncol 2012; 30:(Suppl; abstr 4571).
20. Smith DC, Tangen CM, Van Veldhuizen PJ Jr, et al. Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarci-noma: Southwest Oncology Group S0032. Urology 2011; 77:1172-1176.
21. Gravis G, Fizazi K, Joly Lobbedez F, et al. Survival analysis of a randomized phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-sensitive metastatic prostate cancer (GETUG-AFU 15/0403). In: ESMO; 2012; Vienna; 2012. p. abstr 8930.
22. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351:1488-1490.
23. Basch E, Ryan CJ, Kheoh T, et al. The impact of abiraterone acetate (AA) therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer (MCRPC). Ann Oncol 2012; 23:abstr 8930.
24. Taplin ME, Chu F, Morrison JP, et al. ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy näive patients with castration resistant prostate cancer (CRPC). In: American Association for Cancer Research Annual Meeting; 2012; Chicago, IL; 2012. p. abstr CT-07.
25. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446.
26. Rathkopf DE, Danila DC, Morris MJ, et al. Phase I/II safety and pharmaco-kinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study. J Clin Oncol 2012; 30:(Suppl 5; abstr 43).
27. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959-1966.
28. Nelson JB, Fizazi K, Miller K, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012; 118:5709-5718.
29. Armstrong AJ, Haggman M, Stadler WM, et al. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial. J Clin Oncol 2012; 30:(Suppl; abstr 4550).
30. Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29:4022-4028.
31. Chi K, Yu EY, Ellard S, et al. A randomized phase II study of OGX-427 plus prednisone (P) vs. P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). Ann Oncol 2012; 23:abstr 900PD.
32. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
33. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-1105.
34. McNeel DG, Smith HA, Eickhoff JC, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012; 61:1137-1147.
35. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-517.
36. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501-508.
37. Bousquet G, Alexandre J, Le Tourneau C, et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer 2011; 105:1640-1645.
38. Mardjuadi F, Medioni J, Kerger J, et al. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naive patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 2012; 70:293-303.
39. Zurita AJ, George DJ, Shore ND, et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol 2012; 23:688-694.
40. Tannock I, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE). J Clin Oncol 2013;31:(suppl 6; abstr 13).
41. Vogelzang NJ, Ely B, Fink LM, et al. Circulating tumor cell counts (CTC) as prognostic ofoverall survival (OS)inSWOG S0421-docetaxel withor without atrasentan for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2012; 30:(Suppl; abstr 10503).
42. Araujo JC, Trudel GC, Saad F, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol 2013;31:(suppl 6; abstr LBA8).
43. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Ann Oncol 2013; 31:412-419.
44. Alva A, Slovin S, Daignault S, et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with nonmetastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2012; 30:749-757.
45. de Bono JS, Smith MR, Rathkopf D, et al. Cabozantinib (XL184) at 40mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 nonrandomized expansion cohort (NRE). Ann Oncol 2012; 23:abstr 8970.
46. Lee RJ, Michaelson MD, Saylor PJ, et al. Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: a dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases. J Clin Oncol 2012; 30:(Suppl; abstr 4566).
47. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813-822.
48. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27:954-958.
49. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44:519-526.
50. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63:940-945.
51. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multi-center phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012; 48:678-686.